Noncentral nervous system systemic embolism in patients with atrial fibrillation: Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)

Ryan Orgel; Daniel Wojdyla; David Huberman; Jonathan L. Halperin; Günter Breithardt; Daniel E. Singer; Keith A.A. Fox; Graeme J. Hankey; Kenneth W. Mahaffey; W. Schuyler Jones; Manesh R. Patel

doi:10.1161/CIRCOUTCOMES.116.003520

Noncentral nervous system systemic embolism in patients with atrial fibrillation: Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)

Ryan Orgel, Daniel Wojdyla, David Huberman, Jonathan L. Halperin, Günter Breithardt, Daniel E. Singer, Keith A.A. Fox, Graeme J. Hankey, Kenneth W. Mahaffey, W. Schuyler Jones, Manesh R. Patel

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English
Article number	e003520
Journal	Circulation: Cardiovascular Quality and Outcomes
Volume	10
Issue number	5
DOIs	https://doi.org/10.1161/CIRCOUTCOMES.116.003520
State	Published - 1 May 2017

Access to Document

10.1161/CIRCOUTCOMES.116.003520

Cite this

Orgel, R., Wojdyla, D., Huberman, D., Halperin, J. L., Breithardt, G., Singer, D. E., Fox, K. A. A., Hankey, G. J., Mahaffey, K. W., Jones, W. S., & Patel, M. R. (2017). Noncentral nervous system systemic embolism in patients with atrial fibrillation: Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). Circulation: Cardiovascular Quality and Outcomes, 10(5), Article e003520. https://doi.org/10.1161/CIRCOUTCOMES.116.003520

Orgel, Ryan ; Wojdyla, Daniel ; Huberman, David et al. / Noncentral nervous system systemic embolism in patients with atrial fibrillation : Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). In: Circulation: Cardiovascular Quality and Outcomes. 2017 ; Vol. 10, No. 5.

@article{1a3c96d756aa40a6a9fe23b0990ab2e3,

title = "Noncentral nervous system systemic embolism in patients with atrial fibrillation: Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)",

author = "Ryan Orgel and Daniel Wojdyla and David Huberman and Halperin, {Jonathan L.} and G{\"u}nter Breithardt and Singer, {Daniel E.} and Fox, {Keith A.A.} and Hankey, {Graeme J.} and Mahaffey, {Kenneth W.} and Jones, {W. Schuyler} and Patel, {Manesh R.}",

note = "Funding Information: ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) was supported by Johnson & Johnson Pharmaceutical Research and Development and Bayer HealthCare. D. Huberman was supported by the National Institutes of Health (grant T32 HL079896).",

year = "2017",

month = may,

day = "1",

doi = "10.1161/CIRCOUTCOMES.116.003520",

language = "English",

volume = "10",

journal = "Circulation: Cardiovascular Quality and Outcomes",

issn = "1941-7713",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "5",

}

Orgel, R, Wojdyla, D, Huberman, D, Halperin, JL, Breithardt, G, Singer, DE, Fox, KAA, Hankey, GJ, Mahaffey, KW, Jones, WS & Patel, MR 2017, 'Noncentral nervous system systemic embolism in patients with atrial fibrillation: Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)', Circulation: Cardiovascular Quality and Outcomes, vol. 10, no. 5, e003520. https://doi.org/10.1161/CIRCOUTCOMES.116.003520

Noncentral nervous system systemic embolism in patients with atrial fibrillation: Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). / Orgel, Ryan; Wojdyla, Daniel; Huberman, David et al.
In: Circulation: Cardiovascular Quality and Outcomes, Vol. 10, No. 5, e003520, 01.05.2017.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Noncentral nervous system systemic embolism in patients with atrial fibrillation

T2 - Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)

AU - Orgel, Ryan

AU - Wojdyla, Daniel

AU - Huberman, David

AU - Halperin, Jonathan L.

AU - Breithardt, Günter

AU - Singer, Daniel E.

AU - Fox, Keith A.A.

AU - Hankey, Graeme J.

AU - Mahaffey, Kenneth W.

AU - Jones, W. Schuyler

AU - Patel, Manesh R.

N1 - Funding Information: ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) was supported by Johnson & Johnson Pharmaceutical Research and Development and Bayer HealthCare. D. Huberman was supported by the National Institutes of Health (grant T32 HL079896).

PY - 2017/5/1

Y1 - 2017/5/1

UR - http://www.scopus.com/inward/record.url?scp=85019397661&partnerID=8YFLogxK

U2 - 10.1161/CIRCOUTCOMES.116.003520

DO - 10.1161/CIRCOUTCOMES.116.003520

M3 - Article

C2 - 28495674

AN - SCOPUS:85019397661

SN - 1941-7713

VL - 10

JO - Circulation: Cardiovascular Quality and Outcomes

JF - Circulation: Cardiovascular Quality and Outcomes

IS - 5

M1 - e003520

ER -

Orgel R, Wojdyla D, Huberman D, Halperin JL, Breithardt G, Singer DE et al. Noncentral nervous system systemic embolism in patients with atrial fibrillation: Results From ROCKET AF (rivaroxaban once daily, oral, direct factor xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). Circulation: Cardiovascular Quality and Outcomes. 2017 May 1;10(5):e003520. doi: 10.1161/CIRCOUTCOMES.116.003520